Other

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Bristol-myers Squibb Compnay

Université Louis Pasteur

UniversitÉde Strasbourg

Universidade De Vito

Radboud University Nijmegen

Association Pour Le Development De La Recherche En Genetique Moleculaire (aderegem)

Seconda Università Degli Studi Di Napoli

Universidad De Vigo

Radbound University Nijmegen

Hinrich Gronemeyer

Pierre H Chambon

Peter R Reczek

Jacek Ostrowski

Johannes Voegel

Marco Gottardis

Daniel Metzger

Angel De Lera

Yves Lutz

Michel Lanotte

Jean-Claude Nicolas

Sylvie Roux

G&eacute;rard Benoit

Jacques Bertrand Brocard

Hendrik Gerard Stunnenberg

Lucia Altucci

Pierre Chambon

Derivatives of psammaplin A responding to formula (I), a method for their synthesis and their use for the preparation of a medicament for preventing and for treating a tumor or a cancer. Formula (I). 

Derivatives of psammaplin A, a method for their synthesis and their uses for the prevention or treatment of cancer

The present invention concerns a nuclear receptor (NR) transcriptional mediator. More specifically, isolated nucleic acid molecules are provided encoding transcriptional intermediary factor-2 (TIF2). Recombinant methods for making TIF2 polypeptides are also provided as are TIF2 antibodies. Screening methods are also provided for identifying agonists and antagonists of the activation function AF-2 of nuclear receptors, for identifying agonists and antagonists of the AD1 activation domain activity of TIF2, and for identifying agonists and antagonists of the AD2 activation domain activity of TIF2.

Transcriptional intermediary factor-2

A DNA fragment coding for a modified nuclear glucocorticoid receptor, particularly one mutated in the region coding for the ligand binding domain, so that receptor activity is more strongly inducible by a synthetic glucocorticoid ligand than by a natural glucocorticoid ligand, is disclosed. A recombination system inducible in mammals by means of a fusion protein produced between a recombinase and the binding domain of the ligand derived from the modified glucocorticoid receptor of which the activity is more strongly inducible by synthetic glucocorticoids than by natural glucocorticoids, is also disclosed.

Modified nuclear glucocorticoid receptor, fusion protein, and DNA fragments coding for said receptor and said fusion protein

The present invention provides compositions and methods for treating an animal, preferably a human, suffering from or predisposed to a physical disorder by administering an effective amount of a composition comprising at least one RAR antagonist, preferably an RAR&agr; antagonist, and at least one RXR agonist. The combination of an RXR agonist, which has no therapeutic effects alone, with an RAR antagonist allows the use of lower doses of the RAR antagonist than were previously thought to be efficacious; this approach obviates many of the undesirable physiological side-effects of treatment with RAR antagonists.

Therapeutic combinations of RAR antagonists and RXR agonists and use thereof

The invention relates to compositions comprising a retinoid X receptor agonist and an agent capable of activating protein kinase A. The invention also relates to methods of treating hyperproliferative diseases by administering a retinoid X receptor agonist and an agent capable of activating protein kinase A.

Compositions and methods for treatment of hyperproliferative diseases

Polynucleotide encoding transcriptional intermediary factor-2

The present invention provides compositions and methods for treating an animal, preferably a human, suffering from or predisposed to a physical disorder by administering an effective amount of a composition comprising at least one RAR antagonist, preferably an RAR.alpha. antagonist, and at least one RXR agonist. The combination of an RXR agonist, which has no therapeutic effects alone, with an RAR antagonist allows the use of lower doses of the RAR antagonist than were previously thought to be efficacious; this approach obviates many of the undesirable physiological side-effects of treatment with RAR antagonists.

Therapeutic combinations of RAR antagonists and RXR agonists and use

Growing community of inventors

Oberkirch, Germany

Hinrich Gronemeyer